Beam Therapeutics is trading 5.2% down at $33.97 today, primarily impacted by an arbitration tribunal's decision in favor of Prime Medicine regarding their 2019 collaboration. - The ruling, announced on July 8, 2026, allows Prime Medicine to continue developing its PM647 drug for Alpha-1 Antitrypsin Deficiency (AATD) without breach of agreement or monetary damages to Beam. - This comes after a recent uptrend in Beam's shares, fueled by positive regulatory news like the FDA clearance of BEAM-304 for PKU in June 2026 and encouraging clinical data from the BEAM-302 trial for AATD.